Litcius/Paper detail

Series of Desloratadine Platinum(IV) Hybrids Displaying Potent Antimetastatic Competence by Inhibiting Epithelial–Mesenchymal Transition and Arousing Immune Response

Ming Zhang, Yan Chen, Zhifang Liu, Min Liu, Qingpeng Wang

2024Journal of Medicinal Chemistry20 citationsDOI

Abstract

Metastasis is the major obstacle to the survival of cancer patients. Herein, a series of new desloratadine platinum(IV) conjugates with promising antiproliferative and antimetastatic activities were developed and evaluated. The candidate complex caused significant DNA damage and stimulated mitochondrial apoptosis through the Bcl-2/Bax/caspase3 pathway. Then, it suppressed the epithelial–mesenchymal transition (EMT) process in tumors effectively through NMT-1/HPCAL1 and β-catenin signaling. Subsequently, the angiogenesis was inhibited with the downregulation of key proteins HIF-1α, VEGFA, MMP-9, and CD34. Moreover, the antitumor immunity was effectively aroused by the synergism of EMT reversion and decrease of the histamine level; then, the macrophage polarization from M2- to M1-type and the increase of CD4 + and CD8 + T cells were triggered simultaneously in tumors.

Topics & Concepts

ChemistryCancer researchEpithelial–mesenchymal transitionAngiogenesisApoptosisMacrophage polarizationDownregulation and upregulationBiochemistryMacrophageBiologyIn vitroGeneCancer Mechanisms and TherapyHistone Deacetylase Inhibitors ResearchImmune cells in cancer
Series of Desloratadine Platinum(IV) Hybrids Displaying Potent Antimetastatic Competence by Inhibiting Epithelial–Mesenchymal Transition and Arousing Immune Response | Litcius